{"analyses":[{"ciLowerLimit":"0.75","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.41","estimateComment":"From unstratified Cox proportional hazard model","groupDescription":"PD-L1 Negative","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"1.03"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.72","upperLimit":"13.21","value":"11.14"},{"groupId":"OG001","lowerLimit":"8.05","upperLimit":"17.81","value":"11.76"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"description":"Overall Survival (OS) by PD-L1 expression was defined the time between the date of randomization to the date of death. For participants without documentation of death, OS was censored on the last date the participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg IV over 60 minutes Q2W","id":"OG000","title":"Nivolumab"},{"description":"Dacarbazine: 1000 mg/m\\^2 IV Q3W Carboplatin: Area under the concentration-time curve (AUC) 6 IV Q3W Paclitaxel: 175 mg/m\\^2 IV Q3W","id":"OG001","title":"Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)"}],"paramType":"MEDIAN","populationDescription":"All PD-L1 negative evaluable participants for OS","reportingStatus":"POSTED","timeFrame":"Up to 96 months","title":"Overall Survival (OS) by PD-L1 Negative","type":"SECONDARY","unitOfMeasure":"Months"}